175 related articles for article (PubMed ID: 32554613)
1. FcγRII (CD32) modulates antibody clearance in NOD SCID mice leading to impaired antibody-mediated tumor cell deletion.
Oldham RJ; Mockridge CI; James S; Duriez PJ; Chan HTC; Cox KL; Pitic VA; Glennie MJ; Cragg MS
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554613
[TBL] [Abstract][Full Text] [Related]
2. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
[TBL] [Abstract][Full Text] [Related]
3. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
Xiu Y; Wong CP; Bouaziz JD; Hamaguchi Y; Wang Y; Pop SM; Tisch RM; Tedder TF
J Immunol; 2008 Mar; 180(5):2863-75. PubMed ID: 18292508
[TBL] [Abstract][Full Text] [Related]
4. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
5. Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.
Wen J; Wang L; Ren J; Kranz E; Chen S; Wu D; Kanazawa T; Chen I; Lu Y; Kamata M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593826
[TBL] [Abstract][Full Text] [Related]
6. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
Sharma SK; Chow A; Monette S; Vivier D; Pourat J; Edwards KJ; Dilling TR; Abdel-Atti D; Zeglis BM; Poirier JT; Lewis JS
Cancer Res; 2018 Apr; 78(7):1820-1832. PubMed ID: 29363548
[TBL] [Abstract][Full Text] [Related]
7. Ligation of Fc gamma RII (CD32) pivotally regulates survival of human eosinophils.
Kim JT; Schimming AW; Kita H
J Immunol; 1999 Apr; 162(7):4253-9. PubMed ID: 10201955
[TBL] [Abstract][Full Text] [Related]
8. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
Arriga R; Caratelli S; Lanzilli G; Ottaviani A; Cenciarelli C; Sconocchia T; Spagnoli GC; Iezzi G; Roselli M; Lauro D; Coppola A; Dotti G; Ferrone S; Sconocchia G
Int J Cancer; 2020 May; 146(9):2531-2538. PubMed ID: 31396956
[TBL] [Abstract][Full Text] [Related]
9. Mouse Strains Influence Clearance and Efficacy of Antibody and Antibody-Drug Conjugate Via Fc-FcγR Interaction.
Li F; Ulrich ML; Shih VF; Cochran JH; Hunter JH; Westendorf L; Neale J; Benjamin DR
Mol Cancer Ther; 2019 Apr; 18(4):780-787. PubMed ID: 30824607
[TBL] [Abstract][Full Text] [Related]
10. Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions.
Sibéril S; de Romeuf C; Bihoreau N; Fernandez N; Meterreau JL; Regenman A; Nony E; Gaucher C; Glacet A; Jorieux S; Klein P; Hogarth MP; Fridman WH; Bourel D; Béliard R; Teillaud JL
Clin Immunol; 2006; 118(2-3):170-9. PubMed ID: 16332457
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases.
Carreno BM; Garbow JR; Kolar GR; Jackson EN; Engelbach JA; Becker-Hapak M; Carayannopoulos LN; Piwnica-Worms D; Linette GP
Clin Cancer Res; 2009 May; 15(10):3277-86. PubMed ID: 19447870
[TBL] [Abstract][Full Text] [Related]
12. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
13. Unique monoclonal antibodies define expression of Fc gamma RI on macrophages and mast cell lines and demonstrate heterogeneity among subcutaneous and other dendritic cells.
Tan PS; Gavin AL; Barnes N; Sears DW; Vremec D; Shortman K; Amigorena S; Mottram PL; Hogarth PM
J Immunol; 2003 Mar; 170(5):2549-56. PubMed ID: 12594281
[TBL] [Abstract][Full Text] [Related]
14. Impact of altered endogenous IgG on unspecific mAb clearance.
Fuhrmann S; Kloft C; Huisinga W
J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
16. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
17. Field flow fractionation for assessing neonatal Fc receptor and Fcγ receptor binding to monoclonal antibodies in solution.
Pollastrini J; Dillon TM; Bondarenko P; Chou RY
Anal Biochem; 2011 Jul; 414(1):88-98. PubMed ID: 21385563
[TBL] [Abstract][Full Text] [Related]
18. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
[TBL] [Abstract][Full Text] [Related]
19. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
20. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]